Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced September 22, 2026 Report an issue

ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

244

Shown on this page

Current sort

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 244 matching trials for Prostate Cancer.

Live ClinicalTrials.gov results.

Active filters: "CRPC" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer, Hormone Sensitive Prostate Cancer, Non-metastatic Prostate Cancer
Interventions: Darolutamide, Enzalutamide; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Fairway, Kansas + 4 more

Conditions: Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
Interventions: JANX013, JANX007; Drug
Lead sponsor: Janux Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: Darolutamide (BAY1841788, Nubeqa), ADT; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 31
States / cities: Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Prostate Cancer
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-HBED-CC; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana • New York, New York

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 20
States / cities: Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more

Conditions: Prostatic Neoplasm
Interventions: AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more

Conditions: Prostate Cancer
Interventions: BMS-986165, Degarelix; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more

Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Interventions: Cabozantinib, Nivolumab; Drug
Lead sponsor: Rana McKay, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Chicago, Illinois • Dallas, Texas + 1 more

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: AB-3028; Biological
Lead sponsor: Arsenal Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 6 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI; Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 129
States / cities: Anchorage, Alaska • Bakersfield, California • Irvine, California + 106 more

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Therapy, Apalutamide, Docetaxel, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, PSMA PET Scan, Biospecimen Collection, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 210
States / cities: Tucson, Arizona • Dublin, California • Fremont, California + 170 more

About this Prostate Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Prostate Cancer clinical trials

How Prostate Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

About this Prostate Cancer clinical trials directory page